Angiogenesis and prostate cancer: Important laboratory and clinical findings

[1]  H. Gustavsson,et al.  Transition of an androgen‐dependent human prostate cancer cell line into an androgen‐independent subline is associated with increased angiogenesis , 2005, The Prostate.

[2]  A. D'Amico,et al.  Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. , 2004, The Journal of urology.

[3]  Vincenzo Valentini,et al.  Targeted inhibition of the epidermal growth factor receptor‐tyrosine kinase by ZD1839 (‘Iressa’) induces cell‐cycle arrest and inhibits proliferation in prostate cancer cells , 2004, Journal of cellular physiology.

[4]  Eric Small,et al.  Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate‐specific antigen level after radical prostatectomy and/or radiation therapy , 2004, Cancer.

[5]  S. Steinberg,et al.  Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  G. Macpherson,et al.  Antitumor Effects of Thalidomide Analogs in Human Prostate Cancer Xenografts Implanted in Immunodeficient Mice , 2004, Clinical Cancer Research.

[7]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[8]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[9]  A. Davidoff,et al.  Endostatin-mediated concomitant resistance in neuroblastoma. , 2004, Journal of pediatric surgery.

[10]  R. Pazdur,et al.  United States Food and Drug Administration Drug Approval Summary , 2004, Clinical Cancer Research.

[11]  L. Chung,et al.  Targeting Angiogenic Pathways Involving Tumor–stromal Interaction to Treat Advanced Human Prostate Cancer , 1998, Cancer and Metastasis Reviews.

[12]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[13]  Dan Theodorescu,et al.  Angiogenesis and prostate cancer tumor growth , 2004, Journal of cellular biochemistry.

[14]  W. Figg,et al.  Antiangiogenesis in prostate cancer , 2004 .

[15]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[16]  M. Gütschow,et al.  Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues. , 2003, Cancer research.

[17]  D. Neal,et al.  An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer , 2003, British Journal of Cancer.

[18]  Carlos L Arteaga,et al.  ErbB-targeted therapeutic approaches in human cancer. , 2003, Experimental cell research.

[19]  W. M. Linehan,et al.  National Cancer Institute intramural approach to advanced prostate cancer. , 2002, Clinical prostate cancer.

[20]  Y. Ando,et al.  Pharmacogenetic Associations of CYP2C19 Genotype with In Vivo Metabolisms and Pharmacological Effects of Thalidomide , 2002, Cancer biology & therapy.

[21]  K. Gibson,et al.  ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. , 2002, Cancer research.

[22]  W. Figg,et al.  Thalidomide metabolism by the CYP2C subfamily. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  S. Steinberg,et al.  A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  E. Small,et al.  An update on prostate cancer , 2001, Current opinion in oncology.

[25]  Shahin Rafii,et al.  Role of Angiogenesis in the Progression and Treatment of Prostate Cancer , 2001, Cancer investigation.

[26]  B. Spiegelman,et al.  Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Sander Kersten,et al.  Roles of PPARs in health and disease , 2000, Nature.

[28]  D. Tindall,et al.  Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor γ ligand, 15-deoxy-Δ12,14-prostaglandin J2 , 2000 .

[29]  H. Redmond,et al.  Significance of angiogenesis in cancer therapy , 1998, The British journal of surgery.

[30]  H P Koeffler,et al.  Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. , 1998, Cancer research.

[31]  W. Figg,et al.  Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. , 1998, Biochemical pharmacology.

[32]  J. Folkman.  Clinical Applications of Research on Angiogenesis , 1995 .

[33]  R. D'Amato,et al.  Thalidomide is an inhibitor of angiogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[34]  W Blumenfeld,et al.  Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. , 1993, The American journal of pathology.

[35]  J. Folkman.  What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[36]  S. Weinreb,et al.  Teratogen metabolism: thalidomide activation is mediated by cytochrome P-450. , 1986, Toxicology and applied pharmacology.

[37]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[38]  J Folkman,et al.  Transplacental carcinogenesis by stilbestrol. , 1971, The New England journal of medicine.